Suscripción a Biblioteca: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Publicado 6 números por año

ISSN Imprimir: 0743-4863

ISSN En Línea: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Drug Delivery Systems for the Treatment of Restenosis

Volumen 17, Edición 3, 2000, 36 pages
DOI: 10.1615/CritRevTherDrugCarrierSyst.v17.i3.20
Get accessGet access

SINOPSIS

Attempts to achieve revascularization of coronary arteries blocked by atherosclerotic plaques are hampered by restenotic hyperproliferative response of die treated vessels. The uniform failure of clinical trials using systemic therapies to prevent restenosis has prompted development of methods for arterial drug delivery systems. This review describes technologies of polymeric-based, perivascular, and intraluminal drug and gene delivery systems. The critical assessment of controversies including drug and vehicle type, dose and release rate, and preclinical validation is reviewed.

CITADO POR
  1. Cohen-Sela Einat, Elazar Victoria, Epstein-Barash Hila, Golomb Gershon, Nano-Carriers of Drugs and Genes for the Treatment of Restenosis, in Nanoparticulate Drug Delivery Systems, 20075578, 2007. Crossref

  2. Sharkawi Tahmer, Cornhill Frederick, Lafont Antoine, Sabaria Patrick, Vert Michel, Intravascular bioresorbable polymeric stents: A potential alternative to current drug eluting metal stents, Journal of Pharmaceutical Sciences, 96, 11, 2007. Crossref

  3. Feng Si-Shen, Nanoparticles of biodegradable polymers for new-concept chemotherapy, Expert Review of Medical Devices, 1, 1, 2004. Crossref

  4. Huang Guofeng, Zhou Zhongmin, Srinivasan Rekha, Penn Marc S., Kottke-Marchant Kandice, Marchant Roger E., Gupta Anirban S., Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets, Biomaterials, 29, 11, 2008. Crossref

  5. Chorny Michael, Fishbein Ilia, Danenberg Haim D, Golomb Gershon, Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics, Journal of Controlled Release, 83, 3, 2002. Crossref

  6. Cohen-Sacks Hagit, Elazar Victoria, Gao Jianchuan, Golomb Assaf, Adwan Hassan, Korchov Nikoly, Levy Robert J, Berger Martin R, Golomb Gershon, Delivery and expression of pDNA embedded in collagen matrices, Journal of Controlled Release, 95, 2, 2004. Crossref

  7. Bohl Masters Kristyn S., Lipke Elizabeth A., Rice Elizabeth E. H., Liel Meghan S., Myler Heather A., Zygourakis Corinna, Tulis David A., West Jennifer L., Nitric oxide-generating hydrogels inhibit neointima formation, Journal of Biomaterials Science, Polymer Edition, 16, 5, 2005. Crossref

  8. Westedt Ulrich, Kalinowski Marc, Wittmar Matthias, Merdan Thomas, Unger Florian, Fuchs Jutta, Schäller Susann, Bakowsky Udo, Kissel Thomas, Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment, Journal of Controlled Release, 119, 1, 2007. Crossref

  9. Zweers Miechel L.T., Engbers Gerard H.M., Grijpma Dirk W., Feijen Jan, Release of anti-restenosis drugs from poly(ethylene oxide)-poly(dl-lactic-co-glycolic acid) nanoparticles, Journal of Controlled Release, 114, 3, 2006. Crossref

  10. Epstein Hila, Afergan Eyal, Koroukhov Nickolay, Eisenberg Galit, Gutman Dikla, Golomb Gershon, Liposomal Bisphosphonates for the Treatment of Restenosis, in Liposome Technology, Volume II, 2006. Crossref

  11. Shi Xudong, Chen Guojun, Guo Lian-Wang, Si Yi, Zhu Men, Pilla Srikanth, Liu Bo, Gong Shaoqin, Kent K. Craig, He Xiaoming, Periadventitial Application of Rapamycin-Loaded Nanoparticles Produces Sustained Inhibition of Vascular Restenosis, PLoS ONE, 9, 2, 2014. Crossref

  12. Varshosaz J., Soheili M., Production andin vitrocharacterization of lisinopril-loaded nanoparticles for the treatment of restenosis in stented coronary arteries, Journal of Microencapsulation, 25, 7, 2008. Crossref

  13. Sarısözen Can, Arıca Betül, Orman Mehmet N., Hıncal A. Atilla, Çalış Sema, Optimization of prednisolone acetate-loaded chitosan microspheres using a 23factorial design for preventing restenosis, Drug Delivery, 17, 3, 2010. Crossref

  14. Sarısözen Can, Arıca Betül, Hıncal A. Atilla, Çalış Sema, Development of biodegradable drug releasing polymeric cardiovascular stents andin vitroevaluation, Journal of Microencapsulation, 26, 6, 2009. Crossref

  15. Sachar Ravish, Topol Eric J., Local Gene and Cell Delivery Devices, in Essentials of Restenosis, 2007. Crossref

  16. Epstein Hila , Rabinovich Laura, Banai Shmuel, Elazar Vicktoria, Gao Jianchuan, Chorny Michael, Danenebrg Haim D, Golomb Gershon, Predicting In Vivo Efficacy of Potential Restenosis Therapies by Cell Culture Studies: Species-Dependent Susceptibility of Vascular Smooth Muscle Cells, The Open Cardiovascular Medicine Journal, 2, 1, 2008. Crossref

  17. Fishbein Ilia, Chorny Michael, Alferiev Ivan S., Levy Robert J., Site Specific Controlled Release for Cardiovascular Disease: Translational Directions, in Fundamentals and Applications of Controlled Release Drug Delivery, 2012. Crossref

  18. Aizik Gil, Waiskopf Nir, Agbaria Majd, Ben-David-Naim Meital, Nordling-David Mirjam M., Jbara-Agbaria Doaa, Banin Uri, Golomb Gershon, Targeting and imaging of monocyte-derived macrophages in rat's injured artery following local delivery of liposomal quantum dots, Journal of Controlled Release, 318, 2020. Crossref

  19. Zilberman Meital, Kraitzer Amir, Grinberg Orly, Elsner Jonathan J., Drug-Eluting Medical Implants, in Drug Delivery, 197, 2010. Crossref

  20. Fishbein Ilia, Chorny Michael, Golomb Gershon, Treatment of restenosis by controlled‐release delivery systems of tyrphostins, Drug Development Research, 50, 3-4, 2000. Crossref

  21. Cohen-Sacks H, Najajreh Y, Tchaikovski V, Gao G, Elazer V, Dahan R, Gati I, Kanaan M, Waltenberger J, Golomb G, Novel PDGFβR antisense encapsulated in polymeric nanospheres for the treatment of restenosis, Gene Therapy, 9, 23, 2002. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain